A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055) identifier:
NCT03228667 (

Study Contact Information:

For additional information, please contact:

Jayson Garmizo by phone: 310-912-2230 or by email or

Brooke Greenley by phone: 919-810-0367 or by email.

About the Study

Immune checkpoint inhibitors are immunotherapy drugs that allow the immune system to find and destroy cancer cells.

This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or PD-L1 immune checkpoint inhibitor. NOTE: This study is no longer recruiting.

Type of Study

This is an open-label study. All participants will receive study drugs and all will know which medications they are receiving. Participants will be assigned to one of five groups based on cancer type and response to prior treatment. 

What the Study Entails

All patients in Groups 1-4 will receive treatment with an immune checkpoint inhibitor plus the novel immunotherapy agent N-803 for up to 17 cycles, where each cycle is six weeks in duration.

Some patients in Groups 1-4 whose cancer grows while on study may roll over into Group 5. Group 5 participants will receive treatment with an immune checkpoint inhibitor, the new immunotherapy agents N-803 and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles, where each cycle is six weeks in duration.

Radiologic evaluation will occur at the end of each treatment cycle.

Treatment will continue for up to 2 years, or until the patient experiences progressive disease or an adverse event keeps the participant from continuing in the study.

This Study is Open To:

NOTE: This study is no longer recruiting.

This Study is Not Open To:


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.